TGN S15
Alternative Names: TGN-S15Latest Information Update: 22 Feb 2026
At a glance
- Originator Toragen
- Class Antivirals; Small molecules
- Mechanism of Action Human papillomavirus type 16 oncogene protein E5 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Human papillomavirus infections
Most Recent Events
- 17 Jul 2023 Preclinical trials in Human papillomavirus infection in USA (PO) before July 2023 (Toragen pipeline, July 2023)